65,437 trials
Allergic Rhinitis · Urticaria
Primary: Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test — -0.041 meters
Kidney Transplantation
Primary: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected…
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 19.1; 19.0; 8.3 weeks — p=0.2133
Hemorrhoids, Internal
Primary: Number of Participants With Resolution of Symptoms — 18 participants
Esophageal Cancer · Stomach Cancer
Primary: 10-month Progression-Free Survival Rate — 40.0 probability (%)
Retinitis Pigmentosa
Primary: Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment…
Postpartum Weight Retention
Primary: Body Mass Index (BMI) — 33.62; 28.03; 26.90; 26.99 kg/m^2
Septic Shock
Primary: Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP>60 mmHg) Without Norepinephrine — 20.0; 42.9; 60.0; 7.7 Percentage of patients
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Upper Respiratory Tract Infection · Nasal Congestion · Rhinorrhea
Primary: Physician Global Evaluation of Effectiveness on Nasal Symptoms — 1.9; 2.1 score on a scale
Breast Cancer
Primary: Efficacy Based on the Area Under the Receiver Operating Characteristic (ROC) Curve in Breasts Analyzed With DBT as an Adjunct to FFDM vs. FFDM Alone — 0.8527; 0.7516…
Acute Schizophrenia
Primary: Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C. — 0.292; 3.420 Days — p=<0.0001
Schizophreniform Disorder · Schizoaffective Disorder · Psychosis
Primary: Weight Gain and Other Side Effects
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have · Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants
Rosacea · Erythema
Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065